## **Publications**
<br>

[Focal amplification and overexpression of E3 ubiquitin ligase genes CBLC and SMURF1 in patients with pancreatic ductal adenocarcinoma](https://github.com/jtopham/)

> [In submission](https://github.com/jtopham/)
>

<br>

[Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics](https://github.com/jtopham/)

> [Clinical Cancer Research 2021](https://pubmed.ncbi.nlm.nih.gov/33051307/)
> 

<br>

[Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer](https://github.com/jtopham/)

> [Clinical Cancer Research 2020](https://pubmed.ncbi.nlm.nih.gov/31481506/)
>

<br>

[Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types](https://github.com/jtopham/)

> [Molecular Cancer Therapeutics](https://pubmed.ncbi.nlm.nih.gov/32518206/)
> 

<br>

[Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?](https://github.com/jtopham/)

> [Clinical Cancer Research 2021](https://pubmed.ncbi.nlm.nih.gov/32958704/)
> 

<br>

[Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer](https://github.com/jtopham/)

> [Journal of Clinical Oncology 2023](https://pubmed.ncbi.nlm.nih.gov/36007218/)
> 

<br>

[The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma](https://github.com/jtopham/)

> [Nature Communications 2022](https://pubmed.ncbi.nlm.nih.gov/36028483/)
>

<br>

[Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma](https://github.com/jtopham/)

> [Nature Communications 2022](https://pubmed.ncbi.nlm.nih.gov/36209277/)
> 

<br>
